Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Condition:   Lung Cancer Interventions:   Drug: Pembrolizumab;   Drug: Guadecitabine;   Drug: Mocetinostat Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.;   Astex Pharmaceuticals;   Mirati Therapeutics Inc. Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uJLPpW
via IFTTT